A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
NCT ID: NCT01201317
Last Updated: 2014-04-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
134 participants
INTERVENTIONAL
2010-09-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
NCT01200524
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
NCT01928381
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
NCT02372578
Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy
NCT03755934
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
NCT00939094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD2423, 150 mg
Tablets, 150 mg once daily in the morning.
AZD2423
150 mg tablet
AZD2423, 20 mg
Tablets, 20 mg once daily in the morning.
AZD2423
20 mg tablet
Placebo
Tablets, placebo, once daily in the morning.
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD2423
20 mg tablet
AZD2423
150 mg tablet
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and female of non-child bearing potential patients aged 18 to 80 years
* Patients with neuropathic pain due to painful diabetic polyneuropathy.
Exclusion Criteria
* History of treatment failure with more than three adequate trials of medication for neuropathic pain
* Central neuropathic pain conditions (caused by Central Nervous System injury/disease, eg. Stroke)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bror Jonzon
Role: STUDY_DIRECTOR
AstraZeneca R&D Södertälje
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Goodyear, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Los Angeles, California, United States
Research Site
DeLand, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Sunrise, Florida, United States
Research Site
Madisonville, Kentucky, United States
Research Site
Willingboro, New Jersey, United States
Research Site
New York, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Houston, Texas, United States
Research Site
Winnipeg, Manitoba, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Etobicoke, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Lachine, Quebec, Canada
Research Site
Laval, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2600C00005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.